NasdaqGM - Delayed Quote • USD
Third Harmonic Bio, Inc. (THRD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.31 | -0.32 | -1.32 | -1.69 |
| Low Estimate | -0.36 | -0.35 | -1.39 | -1.9 |
| High Estimate | -0.27 | -0.29 | -1.25 | -1.47 |
| Year Ago EPS | -0.4 | -0.19 | -0.78 | -1.32 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.35 | -0.3 | -0.27 | -0.31 |
| EPS Actual | -0.4 | -0.19 | -0.19 | -0.17 |
| Difference | -0.05 | 0.11 | 0.08 | 0.14 |
| Surprise % | -14.30% | 36.70% | 29.60% | 45.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.31 | -0.32 | -1.32 | -1.69 |
| 7 Days Ago | -0.31 | -0.32 | -1.32 | -1.69 |
| 30 Days Ago | -0.31 | -0.32 | -1.34 | -1.73 |
| 60 Days Ago | -0.3 | -0.33 | -1.38 | -1.96 |
| 90 Days Ago | -0.3 | -0.33 | -1.38 | -1.96 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | THRD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 22.50% | -- | -- | 6.50% |
| Next Qtr. | -68.40% | -- | -- | 12.00% |
| Current Year | -69.20% | -- | -- | 5.30% |
| Next Year | -28.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 8/11/2023 |
| Downgrade | Morgan Stanley: Overweight to Equal-Weight | 12/16/2022 |
| Downgrade | Jefferies: Buy to Hold | 12/16/2022 |
| Initiated | Jefferies: Buy | 10/10/2022 |
| Initiated | Morgan Stanley: Overweight | 10/10/2022 |
| Initiated | Cowen & Co.: Outperform | 10/10/2022 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
PCVX Vaxcyte, Inc.
60.72
+1.10%
ELVN Enliven Therapeutics, Inc.
17.18
+2.38%
IDYA IDEAYA Biosciences, Inc.
39.94
+3.42%
ATXS Astria Therapeutics, Inc.
9.00
-1.85%
KYMR Kymera Therapeutics, Inc.
33.37
+0.06%
DNTH Dianthus Therapeutics, Inc.
21.50
+2.43%
TYRA Tyra Biosciences, Inc.
15.67
+3.71%
TRDA Entrada Therapeutics, Inc.
12.45
+0.73%
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%